科伦药业(002422) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥4,389,897,045, a decrease of 29.42% compared to ¥6,219,417,413 in the same period last year[5] - Net profit attributable to shareholders was ¥584,242,512, down 43.07% from ¥1,026,188,176 year-on-year[5] - Basic and diluted earnings per share were both ¥0.37, reflecting a decline of 44.78% from ¥0.67 in the same period last year[5] - Total operating revenue decreased to ¥4,389,897,045, down 29.5% from ¥6,219,417,413 in the previous period[24] - Net profit for the period was ¥659,587,476, representing a 48.7% decrease from ¥1,285,801,413 in the prior year[25] - The total comprehensive income for the period was CNY 653,323,410, a decrease from CNY 1,284,956,201 in the previous period[26] Cash Flow - The net cash flow from operating activities decreased by 64.86%, amounting to ¥449,384,244 compared to ¥1,278,763,116 in the previous year[10] - Net cash flow from operating activities was CNY 449,384,244, significantly lower than CNY 1,278,763,116 in the previous period[28] - Cash inflow from operating activities totaled CNY 5,184,117,253, compared to CNY 6,561,069,026 in the previous period[27] - Cash outflow from operating activities was CNY 4,734,733,009, down from CNY 5,282,305,910 in the previous period[27] - Net cash flow from investing activities was negative CNY 690,071,360, a decline from positive CNY 670,633,809 in the previous period[28] - Cash inflow from investing activities was CNY 4,018,350,908, compared to CNY 1,772,849,022 in the previous period[28] - Cash outflow from financing activities was CNY 1,063,394,172, down from CNY 1,512,332,605 in the previous period[28] - The ending balance of cash and cash equivalents was CNY 4,075,118,403, down from CNY 6,231,493,756 in the previous period[28] Assets and Liabilities - Total assets increased by 1.37% to ¥37,826,228,881 from ¥37,316,259,482 at the end of the previous year[5] - Current liabilities totaled ¥9,092,533,232, slightly down from ¥9,137,877,768, a decrease of 0.5%[23] - Long-term borrowings decreased to ¥196,000,000 from ¥342,000,000, a reduction of 42.8%[23] - The company's equity attributable to shareholders increased to ¥23,094,459,078, up from ¥22,479,520,446, a rise of 2.7%[23] Investment and Income - Investment income decreased by 45.17%, amounting to ¥61,314,415 compared to ¥111,835,302 in the previous year[9] - The company reported an increase in investment income to ¥61,314,415 from ¥111,835,302, a decline of 45%[25] - The company reported a total investment of 10,000 million in structured deposits with a floating return of 2.50%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,389[11] - Liu Gexin holds 23.72% of the shares, totaling 379,128,280 shares, with 284,346,210 shares under lock-up and 106,014,000 shares pledged[11] - The second largest shareholder, Yaan State-owned Assets Management Co., Ltd., holds 6.07% of the shares, totaling 96,983,174 shares, with 34,010,800 shares pledged[11] - The top 10 shareholders collectively hold significant stakes, with the largest shareholder holding nearly 24%[11] - The company has no preferred shareholders as of the reporting period[12] Research and Development - The company has received approval for its subsidiary's PD-L1 antibody, indicating progress in its product pipeline[18] - A new drug application for the core product, Boduqumab, has been accepted by the National Medical Products Administration, highlighting ongoing R&D efforts[18] - The company has established an exclusive licensing agreement for SKB378/HBM9378, which may enhance its market position[18] Financial Management - The company did not engage in any significant financial management activities during the reporting period[12] - The company plans to continue its financial management strategy, including potential future entrusted wealth management plans[21] Miscellaneous - The company reported a total of 424,982,000.00 in financial assets, with a significant increase in cash and cash equivalents to 4,092,787,913.00 from 3,973,908,715.00[21] - The trading financial assets rose to 2,231,249,987.00, up from 1,921,163,411.00, indicating a growth of approximately 16.2%[21] - Accounts receivable decreased slightly to 4,726,326,218.00 from 4,795,035,595.00, reflecting a reduction of about 1.4%[21] - Inventory levels increased to 3,827,874,323.00 from 3,800,617,271.00, showing a growth of approximately 0.7%[21] - The company completed the cancellation of repurchased shares, indicating a strategic move to enhance shareholder value[19] - The company's first quarter report was not audited[29]